Abstract
Juan Gomez Rivas 1, Rossella Nicoletti 2, Laura Ibáñez 1, Carl Steinbeisser 3, Bertrand de Meulder 4, Asieh Golozar 5, Susan Evans Axelsson 6, Robert Snijder 7, Anders Bjartell 6, Philip Cornford 8, Mieke Van Hemelrijck 9, Katharina Beyer 9, Peter-Paul Willemse 10, Teemu Murtola 11, Monique J Roobol 12, Jesús Moreno-Sierra 1, Riccardo Campi 2, Mauro Gacci 2, Nicolas Mottet 13, Axel Merseburger 14, James Ndow 15
Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone acetate and prednisolone, apalutamide , enzalutamide and darolutamide (in combination with docetaxel chemotherapy) has proven that combination of treatments is more effective. Recently, intensification therapy, so-called “triplets”, have emerged in the armamentarium of mHSPC treatment. Metastatic disease is a clinical state that remains poorly understood. The optimal diagnostic and management of patients with mHSPC are changing thanks to the development of new imaging techniques and therapies. The primary objective of this study is to develop and validate a predictive model for the occurrence of symptomatic progression, initiation of new treatments and death amongst patients with mHSPC treated with one of the approved treatment plans, on characteristics present at admission.
Keywords: PIONEER; androgen deprivation therapy; big data; chemotherapy; metastasis; new androgen receptor-targeted agents; predictive model; prostate cancer.